myostatin inhibitor glp 1 Hanmi Pharm Unveils Next-Generation Obesity Drug Pipeline Targeting Muscle Preservation Beyond GLP-1 Dropping weight while raising the

This article explores evidence-based approaches to managing fatigue during GLP-1 therapy whilst ensuring safe, effective treatment outcomes

Dizziness: if not vertigo could it be cardiac disease

At the crossing of ER stress and MAMs: a key role of sigma-1 receptor

Access disparities exist, with studies suggesting lower utilization rates among Black, Hispanic, and other minority populations despite higher rates of diabetes and obesity in these communities

Peripherally administered GLP-1R and GIPR agonists have also been shown to localize in CVOs, with limited labelling in brain regions shielded by the bloodbrain barrier 13,54,55